ClinicalTrials.gg
CompletedNCT06173115SingleUpdated Oct 2, 2026

Comparison of a Single Versus Double Perclose Technique for TAVR

An interventional study of Perclose Proglide system in Severe Aortic Stenosis, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Completed at 25 sites in China. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Not applicable, Interventional, and Treatment

How we know

Updated Oct 2, 2026Now CompletedStart date moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
876
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Aortic Valve Stenosis with a site in China — 43 open to participants now, 51 under way, 3 of them phase 3. Aortic Valve Stenosis · China.

Enrollment
3rd of 47
876 · median 120
Started
2024
with 10 others
No phase
37 of 69
20 open now
Registered
36th of 69
by date

Among the 69 studies in Aortic Valve Stenosis with a site in China, this one is the 3rd largest by enrollment of the 47 interventional ones that give a count, is one of 11 that started in 2024, is one of 37 with no phase, and was the 36th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

43 of the 69 studies in Aortic Valve Stenosis with a site in China are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Aortic Valve Stenosis with a site in China, or all of them as a file.
02

Study summary

Transcatheter aortic valve replacement (TAVR) has become widely recognized as a minimally invasive approach for aortic valve replacement in patients with severe aortic stenosis. It has been proven to be a safe and effective option for patients who are at low, intermediate, and prohibitive risk for surgical valve replacement.

One of the critical components of procedural success in a transfemoral approach is access site management, as vascular complications strongly correlate with adverse outcomes. When major vascular complications occur, there are higher rates of major bleeding, transfusions, and renal failure requiring dialysis, as well as a significantly higher rate of 30-day and 1-year mortality. In recent years, a "preclosure" technique has emerged as a common vascular closure approach using a Perclose Proglide system (Abbott Vascular), in which sutures are deployed before dilating the arterial access site. This allows for arterial closure after dilation to sizing up to larger bore access sheaths that accommodate valve delivery systems. The sutures are subsequently harvested and tightened to close the large bore arteriotomy site at the end of the case. It has been demonstrated that the use of two Perclose devices, or double Perclose closure, is an effective closure technique with a low rate of vascular complications. A large number of TAVR centers have adopted this method for large-bore vascular closure. In the past, there have been few investigations comparing the utilization of a single Perclose device compared to a double Perclose technique. There are numerous theoretical advantages to the use of a single device, which include decreased procedural cost and procedural time. The investigation aimed to determine if there are clinical benefits as well using the single Perclose approach.

Read the detailed description

SINGLE-CLOSURE (The utilization of Single versus double perclose devices for transfemoral aortIc valve replacement access site Closure) is an investigator-initiated, open-label, multicenter, randomized controlled trial. The study was approved by the local ethics committees of all participating centers, and each patient provided written informed consent for inclusion in the trial. Data management and analysis was performed by an independent data coordinating center, with oversight from a steering committee. The members of the steering committee had full access to the data and vouch for the accuracy and complete- ness of the data and the analyses. The data that support the findings of this study are available from the corresponding author on reasonable request. Patients scheduled to undergo transfemoral TAVR were considered for inclusion in the trial if they met all inclusion and none of the exclusion criteria. Inclusion criteria were an indication for TAVR as judged by the local heart team; selection of the transfemoral access route and a commercially available transcatheter aortic valve; and willingness to comply with protocol specified follow-up evaluations. Principal exclusion criteria were a vascular access site anatomy not suitable for percutaneous vascular closure and the occurrence of vascular access site complications before the TAVR procedure. Additional exclusion criteria were a known allergy or hypersensitivity to any VCD component; unstable active bleeding or bleeding diathesis or significant unman-ageable anemia; absence of computed tomographic data of the access site before the procedure; systemic infection or a local infection at or near the access site; life expectancy of \<6 months because of noncardiac conditions; patients who cannot adhere to or complete the investigational protocol for any reason; pregnant or nursing patients; and participation in any other interventional trial.

The primary end point of the trial was the rate of access site or access-related major and minor vascular complications defined according to the Valve Academic Research Consortium-3 criteria. The end point was assessed during index hospitalization. Relationship to the access site was deter- mined according to the site used for the large-bore vascular access sheath.

Secondary end points included the rate of the primary end point at 30 days; components of the primary end point in-hospital and at 30 days; in-hospital and 30-day major and minor vascular complications; unplanned vascular surgery or use of endovascular stent or stent-graft or other endovascular interventions at the puncture site; in-hospital and 30-day access site- or access-related minor, major, and disabling or life threatening bleeding; need for blood transfusion for access site- or access-related bleeding or vascular complications; rate of VCD failure, defined as the failure of a closure device strategy to achieve hemostasis with the need for an alternative treatment (other than manual compression or adjunctive endovascular ballooning); in-hospital and 30-day all-cause death; in-hospital and 30-day death attributed to access site or access-related complications; need and number of additional unplanned VCDs; time to hemostasis, defined as the time from VCD application to complete hemostasis; and the length of postprocedural hospital stay.

03

Conditions studied

  • Severe Aortic Stenosis

Keywords

  • transcatheter aortic valve replacement
  • vascular closure devices
  • randomized control trial
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients scheduled to undergo transfemoral TAVR were considered for inclusion in the trial if they met all inclusion and none of the exclusion criteria. Inclusion criteria were an indication for TAVR as judged by the local heart team; selection of the transfemoral access route and a commercially available transcatheter aortic valve; and willingness to comply with protocol specified follow-up evaluations.

Exclusion criteria

Exclusion Criteria:

  • Principal exclusion criteria were a vascular access site anatomy not suitable for percutaneous vascular closure and the occurrence of vascular access site complications before the TAVR procedure. Additional exclusion criteria were a known allergy or to any VCD component; unstable active bleeding or bleeding diathesis or significant unman ageable anemia; absence of computed tomographic data of the access site before the procedure; systemic infection or a local infection at or near the access site; of \<6 months because of noncardiac conditions; patients who can-not adhere to or complete the protocol for any reason; pregnant or nursing patients; and participation in any other interventional trial.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
876 participants (actual)

Study arms

  • Active comparator
    Double Perclose device

    Double Perclose device ( Perclose Proglide system, Abbott Vascular) was used for large bore arteriotomy site closure during TF-TAVR procedures

    Device: Perclose Proglide system

  • Experimental
    Single Perclose device

    Single Perclose device ( Perclose Proglide system, Abbott Vascular) was used for large bore arteriotomy site closure during TF-TAVR procedures

    Device: Perclose Proglide system

Interventions

  • DevicePerclose Proglide system

    "Preclosure" technique has emerged as a common vascular closure approach using a Perclose Proglide system (Abbott Vascular), in which sutures are deployed before dilating the arterial access site.

06

What researchers measure

Primary outcomes

  1. The primary end point of the trial was the rate of access site or access-related major and minor vascular complications defined according to the Valve Academic Research Consortium-3 criteria

    1. Aortic dissection or aortic rupture 2. Vascular (arterial or venous) injury (perforation, rupture, dissection, stenosis, ischaemia, arterial or venous thrombosis including pulmonary embolism, arteriovenous fistula, pseudoaneurysm, haematoma, retroperitoneal haematoma, infection) or compartment syndrome resulting in death, VARC type \>\_2 bleeding, limb or visceral ischaemia, or irreversible neurologic impairment; 3. Distal embolization (non-cerebral) from a vascular source resulting in death, amputation, limb or visceral ischaemia, or irreversible endorgan damage; 4. Unplanned endovascular or surgical intervention resulting in death, VARC type \>\_2 bleeding, limb or visceral ischaemia, or irreversible neurologic impairment; 5. Closure device failure c resulting in death, VARC type \>\_2 bleeding, limb or visceral ischaemia, or irreversible neurologic impairment

    Time frame: The end point was assessed during index hospitalization

Secondary outcomes

  1. The rate of the primary end point at 30 days

    the rate of access site or access-related major and minor vascular complications at 30 days

    Time frame: 30 days

  2. Components of the primary end point in-hospital and at 30 days

    Components of the rate of access site or access-related major and minor vascular complications at 30 days

    Time frame: 30 days

  3. In-hospital and 30-day major and minor vascular complications

    In-hospital and 30-day major and minor vascular complications

    Time frame: 30 days

  4. Unplanned vascular surgery or use of endovascular stent or stent-graft or other endovascular interventions at the puncture site

    Unplanned vascular surgery or use of endovascular stent or stent-graft or other endovascular interventions at the puncture site at 30 days

    Time frame: 30 days

  5. in-hospital and 30-day access site- or access-related minor, major, and disabling or life- threatening bleeding; need for blood transfusion for access site or access related bleeding or vascular complications

    in-hospital and 30-day access site- or access-related minor, major, and disabling or life- threatening bleeding; need for blood transfusion for access site or access related bleeding or vascular complications

    Time frame: 30 days

  6. Rate of VCD failure, defined as the failure of a closure device strategy to achieve hemostasis with the need for an alternative treatment (other than manual compression or adjunctive endovascular ballooning)

    Rate of VCD failure, defined as the failure of a closure device strategy to achieve hemostasis with the need for an alternative treatment (other than manual compression or adjunctive endovascular ballooning) at 30 days

    Time frame: 30 days

  7. In-hospital and 30-day all-cause death; in-hospital and 30-day death attributed to access site- access-related complications; need and number of additional unplanned VCDs

    In-hospital and 30-day all-cause death; in-hospital and 30-day death attributed to access site- access-related complications; need and number of additional unplanned VCDs

    Time frame: 30 days

  8. Time to hemostasis, defined as the time from VCD application to complete hemostasis

    Time to hemostasis, defined as the time from VCD application to complete at 30 days

    Time frame: 30 days

  9. The length of postprocedural hospital stay

    The length of postprocedural hospital stay

    Time frame: 30 days

07

Study locations

25 sites
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, Anhui, China
  • Fujian Provincial Hospital
    Fuzhou, Fujian, China
  • The First Hospital of Lanzhou University
    Lanzhou, Gansu, China
  • Nanfang Hospital, Southern Medical University
    Guangzhou, Guangdong, China
  • The First Affiliated Hospital, Sun Yat-sen University
    Guangzhou, Guangdong, China
  • The Affiliated Hospital of Guangdong Medical University
    Zhanjiang, Guangdong, China
  • Yulin First People's Hospital
    Yulin, Guangxi, China
  • Xiangya Hospital of Central South University
    Changshacun, Henan, China
  • Fuwai Central China Cardiovascular Hospital
    Zhengzhou, Henan, China
  • Henan Provincial Chest Hospital
    Zhengzhou, Henan, China
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • General Hospital of Northern Theater Command, PLA
    Shenyang, Liaoning, China
  • Qilu Hospital of Shandong University
    Jinan, Shandong, China
  • Qingdao Municipal Hospital
    Qingdao, Shandong, China
  • The Affiliated Hospital of Qingdao University
    Qingdao, Shandong, China
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi’an, Shanxi, China
  • Sichuan Provincial People's Hospital
    Chengdu, Sichuan, China
  • People's Hospital of Xinjiang Uygur Autonomous Region
    Ürümqi, Xinjiang, China
  • Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University
    Hangzhou, Zhejiang 310000, China
  • Huzhou Central Hospital
    Huzhou, Zhejiang, China
  • Ningbo Medical Center Li Huili Hospital
    Ningbo, Zhejiang, China
  • The First Affiliated Hospital of Ningbo University
    Ningbo, Zhejiang, China
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang, China
  • Beijing Anzhen Hospital, Capital Medical University
    Beijing, China
  • Fuwai Hospital, Chinese Academy of Medical Sciences
    Beijing, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Feb 2026, 24 months.

Of 177 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's 24 months is below that.

Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: start Oct 2023 → Jan 2024, primary completion Apr 2026 → Feb 2026 and completion Jun 2026 → Mar 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2023
First posted
Dec 15, 2023
StartActual
Jan 23, 2024was Oct 2023
Primary completionActual
Feb 13, 2026was Apr 2026
CompletionActual
Mar 19, 2026was Jun 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 2, 2026
Start date
Oct 20, 2023→Jan 23, 2024
Oct 2, 2026
Primary completion
Apr 30, 2026→Feb 13, 2026 (actual)
Oct 2, 2026
Study completion
Jun 28, 2026→Mar 19, 2026 (actual)
Oct 2, 2026
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University→Second Affiliated Hospital, Zhejiang University, School of Medicine
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Recruiting→Completed
    Start date Oct 20, 2023→Jan 23, 2024
    Primary completion Apr 30, 2026→Feb 13, 2026 (now actual)
    Study completion Jun 28, 2026→Mar 19, 2026 (now actual)
    Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University→Second Affiliated Hospital, Zhejiang University, School of Medicine
    + 6 other changes: identifiers, verification date, oversight details, design details, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06173115
Responsible party
Sponsor
First posted
Dec 15, 2023
Start date
Jan 23, 2024
Primary completion
Feb 13, 2026
Completion
Mar 19, 2026
Last update
Oct 2, 2026

Study contacts

Jianan Wang, PhD
study chair · Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion